Glutathione's Role in Cisplatin Resistance in Lung Cancer Cells
Author Information
Author(s): C. Meijer, N.H. Mulder, G.A.P. Hospers, D.R.A. Uges, E.G.E. de Vries
Primary Institution: University Hospital Groningen
Hypothesis
The study investigates how glutathione (GSH) contributes to resistance against cisplatin in small cell lung cancer cells.
Conclusion
The study concludes that increased levels of glutathione and its synthesis capacity in resistant cells contribute to their resistance to cisplatin.
Supporting Evidence
- GLC4-CDDP cells maintained higher levels of glutathione compared to GLC4 cells under cisplatin pressure.
- BSO treatment increased cisplatin-induced cytotoxicity in both cell lines.
- An increase in platinum binding to DNA was observed in GLC4-CDDP cells after glutathione depletion.
Takeaway
This study shows that cancer cells can become resistant to a drug called cisplatin by having more of a protective substance called glutathione.
Methodology
The study used human small cell lung cancer cell lines and a drug called BSO to analyze the role of glutathione in drug resistance.
Limitations
The study may not fully account for all mechanisms of resistance beyond glutathione levels.
Statistical Information
P-Value
p<0.0025
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website